{"id":19664,"date":"2020-03-10T21:31:17","date_gmt":"2020-03-11T01:31:17","guid":{"rendered":"https:\/\/carleton.ca\/coris\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/"},"modified":"2020-04-27T09:32:29","modified_gmt":"2020-04-27T13:32:29","slug":"the-michael-j-fox-foundation-parkinsons-pathway-biomarkers","status":"publish","type":"post","link":"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/","title":{"rendered":"The Michael J. Fox Foundation \u2013 Parkinson\u2019s Pathway Biomarkers"},"content":{"rendered":"<h3>Opportunity<\/h3>\n<p><span class=\"fontstyle0\">Ultimately, our goal is to develop better biomarkers for PD diagnosis, disease progression, patient stratification, and\/or pharmacodynamic readouts for clinical trials. Currently, many efforts are focusing on understanding the role of various cellular processes\/pathways in PD and uncovering novel targets within these pathways for therapeutic development. <\/span><span class=\"fontstyle2\">As such, sensitive biomarker readouts for these targets and pathways will be critical for bridging the gap from basic to translational research\/clinical trials<\/span><span class=\"fontstyle0\">. To accelerate therapeutic development through the development of companion outcome measures\/assays, we are launching this RFA to support critical biomarker development aimed at (1) sensitive measurements of pathway activation\/dysfunction and (2) improving technologies for analyzing<br \/>\nthe target\/pathway of interest.<br \/>\n<\/span><\/p>\n<p><span class=\"fontstyle0\">MJFF considers priority pathways to include: mitochondrial function, lysosomal function, autophagy, inflammation, protein handling, protein trafficking, etc.<br \/>\n<\/span><\/p>\n<p><span class=\"fontstyle3\"><strong>PROGRAM Priorities<\/strong><br \/>\n<\/span><span class=\"fontstyle0\">Applications should focus on studies that achieve one or more of the following goals:<br \/>\n<\/span><\/p>\n<ul>\n<li><span class=\"fontstyle0\">Develop sensitive target or pathway-based outcome measures\/assays for PD to aid diagnostic efforts, tracking disease progression, disease subtyping, patient stratification, pharmacodynamic readouts, or determination of therapeutic efficacy. Novel assay development could include:<\/span>\n<ul style=\"list-style-type: circle\">\n<li><span class=\"fontstyle0\">Developing outcome measures\/assays to measure targets that are sensitive and specific for assessing PD-affected pathways.<br \/>\n<\/span><\/li>\n<li><span class=\"fontstyle0\">Developing\/expanding multiplexed biochemical assays to assess multiple readouts of pathway function\/dysfunction in PD.<\/span><\/li>\n<\/ul>\n<\/li>\n<li><span class=\"fontstyle0\">Optimize existing outcome measures\/assays to assess PD-related pathways or pathway-based targets. Optimization efforts could include:<br \/>\n<\/span><\/p>\n<ul style=\"list-style-type: circle\">\n<li><span class=\"fontstyle0\">Testing existing outcome measures\/assays developed for other disease areas in PD to assist with patient stratification, assessing target\/pathway engagement for clinical trials, or measuring efficacy of a PD therapeutic intervention.<br \/>\n<\/span><\/li>\n<li><span class=\"fontstyle0\">Adaptation of existing assays to different biological matrices to reduce invasiveness of the assay or improve assay sensitivity\/specificity.<br \/>\n<\/span><\/li>\n<li><span class=\"fontstyle0\">Validating promising assays across various performance parameters (e.g., robustness, precision, trueness).<br \/>\n<\/span><\/li>\n<li><span class=\"fontstyle0\">Reformatting promising assays to ensure they use sustainable\/renewable resources or bridging home-brew assays to the commercial space to ensure open accessibility.<\/span><\/li>\n<\/ul>\n<\/li>\n<li><span class=\"fontstyle0\">Work in preclinical models and human biospecimens to develop translational biomarkers that can be assessed in Parkinson\u2019s disease models as well as patient biospecimens using the same matrix and same assay technologies<\/span><\/li>\n<\/ul>\n<h3>Eligibility<\/h3>\n<p><span class=\"fontstyle0\">Applications may be submitted by researchers or clinicians in:<br \/>\n<\/span><span class=\"fontstyle2\">\u2022 <\/span><span class=\"fontstyle0\">U.S. and non-U.S. biotechnology\/pharmaceutical companies, or other publicly or privately held for-profit entities; and<br \/>\n<\/span><span class=\"fontstyle2\">\u2022 <\/span><span class=\"fontstyle0\">U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government.<br \/>\n<\/span><span class=\"fontstyle2\">\u2022 <\/span><span class=\"fontstyle0\">Post-doctoral fellows are <\/span><span class=\"fontstyle3\">not <\/span><span class=\"fontstyle0\">eligible to apply as principal investigators to this program.<\/span><\/p>\n<h3>Funding Available<\/h3>\n<p><span class=\"fontstyle0\">Up to $300,000. Requested support should be commensurate with work proposed. These budgets include direct and indirect costs. MJFF policy is that no more than 15% (non-profit institutions) or 10% (for-profit organizations) of the budget may go to indirect costs. <\/span><\/p>\n<h3>Internal Contacts<\/h3>\n<p>For proposal development\/substantive review, please contact <a href=\"https:\/\/carleton.ca\/ci\/people\/heloise-emdon\/\">Heloise Emdon.<\/a><\/p>\n<h3>Deadlines<\/h3>\n<table style=\"width: 59.5544%;height: 120px\">\n<tbody>\n<tr style=\"height: 48px\">\n<td style=\"height: 48px\">Faculty Deadline<\/td>\n<td style=\"height: 48px\">Consult <a href=\"https:\/\/carleton.ca\/ci\/people\/heloise-emdon\/\">Heloise Emdon<\/a>.<\/td>\n<\/tr>\n<tr style=\"height: 48px\">\n<td style=\"height: 48px\">OVPRI Approval Form Deadline<\/td>\n<td style=\"height: 48px\">April 16, 2020<\/td>\n<\/tr>\n<tr style=\"height: 24px\">\n<td style=\"height: 24px\">Submission to Sponsor<\/td>\n<td style=\"height: 24px\">April 23, 2020 by 5 pm (Pre-Proposal)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Submitting Your Application<\/h3>\n<ul>\n<li><strong>Step 1) Submit an internal Carleton Approval Form<\/strong><br \/>\nSubmit an internal Approval Form through our central awards management database CUResearch:<br \/>\n<a href=\"https:\/\/ovpri.research.carleton.ca\/Romeo.Researcher\/Administrator\/Default.aspx\">https:\/\/ovpri.research.carleton.ca\/Romeo.Researcher\/Administrator\/Default.aspx<\/a><br \/>\nFor a user\u2019s guide on submitting an Approval Form, click <a href=\"https:\/\/carleton.ca\/coris\/wp-content\/uploads\/cuResearch-Users-Manual_June-2019-2.pdf\">here<\/a>.<\/li>\n<li><strong>Step 2) Submit an external application to the granting agency<\/strong><br \/>\nSubmit an external application to the corresponding grant or award agency. For further details about funding categories, eligibility criteria and deadlines for this opportunity, click <a href=\"https:\/\/www.michaeljfox.org\/grant\/parkinsons-pathway-biomarkers?em_cid=mc-a1b1R000008uKNS&amp;et_cid=1526697&amp;et_rid=225019863&amp;et_lid=Parkinson%27s+Pathway+Biomarkers&amp;em_cid=\">here<\/a>.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Opportunity Ultimately, our goal is to develop better biomarkers for PD diagnosis, disease progression, patient stratification, and\/or pharmacodynamic readouts for clinical trials. Currently, many efforts are focusing on understanding the role of various cellular processes\/pathways in PD and uncovering novel targets within these pathways for therapeutic development. As such, sensitive biomarker readouts for these targets [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_mi_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[14],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Michael J. Fox Foundation \u2013 Parkinson\u2019s Pathway Biomarkers - Carleton International<\/title>\n<meta name=\"description\" content=\"Opportunity Ultimately, our goal is to develop better biomarkers for PD diagnosis, disease progression, patient stratification, and\/or pharmacodynamic\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/\",\"url\":\"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/\",\"name\":\"The Michael J. Fox Foundation \u2013 Parkinson\u2019s Pathway Biomarkers - Carleton International\",\"isPartOf\":{\"@id\":\"https:\/\/carleton.ca\/ci\/#website\"},\"datePublished\":\"2020-03-11T01:31:17+00:00\",\"dateModified\":\"2020-04-27T13:32:29+00:00\",\"author\":{\"@id\":\"\"},\"description\":\"Opportunity Ultimately, our goal is to develop better biomarkers for PD diagnosis, disease progression, patient stratification, and\/or pharmacodynamic\",\"breadcrumb\":{\"@id\":\"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/carleton.ca\/ci\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Funding Opportunities\",\"item\":\"https:\/\/carleton.ca\/ci\/category\/funding-opportunities\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"The Michael J. Fox Foundation \u2013 Parkinson\u2019s Pathway Biomarkers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/carleton.ca\/ci\/#website\",\"url\":\"https:\/\/carleton.ca\/ci\/\",\"name\":\"Carleton International\",\"description\":\"Carleton University\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/carleton.ca\/ci\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Michael J. Fox Foundation \u2013 Parkinson\u2019s Pathway Biomarkers - Carleton International","description":"Opportunity Ultimately, our goal is to develop better biomarkers for PD diagnosis, disease progression, patient stratification, and\/or pharmacodynamic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/","url":"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/","name":"The Michael J. Fox Foundation \u2013 Parkinson\u2019s Pathway Biomarkers - Carleton International","isPartOf":{"@id":"https:\/\/carleton.ca\/ci\/#website"},"datePublished":"2020-03-11T01:31:17+00:00","dateModified":"2020-04-27T13:32:29+00:00","author":{"@id":""},"description":"Opportunity Ultimately, our goal is to develop better biomarkers for PD diagnosis, disease progression, patient stratification, and\/or pharmacodynamic","breadcrumb":{"@id":"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/carleton.ca\/ci\/2020\/the-michael-j-fox-foundation-parkinsons-pathway-biomarkers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/carleton.ca\/ci\/"},{"@type":"ListItem","position":2,"name":"Funding Opportunities","item":"https:\/\/carleton.ca\/ci\/category\/funding-opportunities\/"},{"@type":"ListItem","position":3,"name":"The Michael J. Fox Foundation \u2013 Parkinson\u2019s Pathway Biomarkers"}]},{"@type":"WebSite","@id":"https:\/\/carleton.ca\/ci\/#website","url":"https:\/\/carleton.ca\/ci\/","name":"Carleton International","description":"Carleton University","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/carleton.ca\/ci\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":{"Post Thumbnail Icon":null,"Post Thumbnail":null},"_links":{"self":[{"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/posts\/19664"}],"collection":[{"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/comments?post=19664"}],"version-history":[{"count":1,"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/posts\/19664\/revisions"}],"predecessor-version":[{"id":19668,"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/posts\/19664\/revisions\/19668"}],"wp:attachment":[{"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/media?parent=19664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/categories?post=19664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/carleton.ca\/ci\/wp-json\/wp\/v2\/tags?post=19664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}